These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors.
    Author: Bodey B, Bodey B, Siegel SE.
    Journal: Mod Pathol; 1995 Apr; 8(3):333-8. PubMed ID: 7617661.
    Abstract:
    During a systematic cell surface antigen expression profile analysis of 76 primary childhood brain tumors (34 medulloblastomas/primitive neuroectodermal tumors and 42 astrocytomas), we employed the following library of monoclonal antibodies (MoABs): anti-Leu-2/a; anti-Leu-3/a; anti-Leu-M5; anti-Leu-11b; anti-HLA-A, -B, -C; anti-HLA-DR; anti-HLe-1 (leukocyte common antigen); and UJ 308. The MoABs identified the expression of various leukocyte-associated, lymphocyte cell line differentiated, cell surface antigens in childhood brain tumors. The antigens were detected with an indirect, biotin-streptavidin-conjugated alkaline phosphatase (AP) immunocytochemical technique. Leu-2/a+ cells comprise the significant CD8+ cytotoxic T-lymphocyte (CTL) population of the tumor-infiltrating lymphocytes. CTLs are major histocompatibility complex (MHC) class I restricted, tumor-associated antigen-specific, cytotoxic cells and were identified in 58 of 76 (76.32%) brain tumors. CTLs usually represented 1-10% of all cells, but in some cases 30-44% of the cells were CD8+. CD4+, MHC class II restricted helper lymphocytes, detected with MoAB anti-Leu-3/a, were present in 65 of 76 (85.53%) brain tumors. Usually 1-10% of the observed cells reacted with MoAB anti-Leu 3/a. Macrophages (Leu-M5 antigen-positive cells) were expressed in 74 of 76 (97.37%) brain tumors. Their number also represented 1-10% of all observed cells in the frozen brain tumor sections. All 76 (100%) brain tumors contained cells that reacted positively with MoABs anti-HLA-A, -B, -C and anti-HLA-DR, demonstrating a strong MHC class I restriction of the tumor cell population and an overall leukocyte antigen expression.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]